Literature DB >> 9918262

Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis.

K Shojania1, B E Koehler, T Elliott.   

Abstract

A 77-year-old man with type II diabetes taking a stable dose of subcutaneous, twice daily human insulin developed symmetrical, inflammatory, rheumatoid factor positive polyarthritis. Within 2 weeks of starting therapy with prednisone 5 mg daily and hydroxychloroquine 400 mg daily he had 2 episodes of severe hypoglycemic coma requiring emergency care. His blood glucose became controlled again when his insulin was decreased by 37%. There are no reported cases of hypoglycemia in diabetic or nondiabetic patients treated with hydroxychloroquine. Hydroxychloroquine has been reported to reduce insulin requirements in refractory type II diabetes by an average of 30%. When hydroxychloroquine is initiated for the treatment of polyarthritis in a type II diabetic requiring insulin or sulfonylurea treatment, blood glucose levels should be monitored closely and the insulin dose may need to be reduced.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9918262

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  18 in total

Review 1.  Drug-induced endocrine and metabolic disorders.

Authors:  Ronald C W Ma; Alice P S Kong; Norman Chan; Peter C Y Tong; Juliana C N Chan
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

2.  Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Sara Kaprove Penn; Amy H Kao; Laura L Schott; Jennifer R Elliott; Frederico G S Toledo; Lewis Kuller; Susan Manzi; Mary Chester M Wasko
Journal:  J Rheumatol       Date:  2010-05-01       Impact factor: 4.666

Review 3.  COVID-19 as an Acute Inflammatory Disease.

Authors:  Rose H Manjili; Melika Zarei; Mehran Habibi; Masoud H Manjili
Journal:  J Immunol       Date:  2020-05-18       Impact factor: 5.422

Review 4.  A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory role.

Authors:  Mirella P Hage; Marwa R Al-Badri; Sami T Azar
Journal:  Ther Adv Endocrinol Metab       Date:  2014-08       Impact factor: 3.565

Review 5.  Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.

Authors:  David N Juurlink
Journal:  CMAJ       Date:  2020-04-08       Impact factor: 8.262

6.  Hydroxychloroquine: a diabetic drug in disguise?

Authors:  Lydia Kang; Ted R Mikuls; James R O'Dell
Journal:  BMJ Case Rep       Date:  2009-03-02

Review 7.  Drug-induced hypoglycaemia: an update.

Authors:  Chaker Ben Salem; Neila Fathallah; Houssem Hmouda; Kamel Bouraoui
Journal:  Drug Saf       Date:  2011-01-01       Impact factor: 5.606

8.  Hydroxychloroquine as a glucose lowering drug.

Authors:  Elizabeth Martha Winter; Anita Schrander-van der Meer; Carmen Eustatia-Rutten; Martien Janssen
Journal:  BMJ Case Rep       Date:  2011-10-28

Review 9.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

10.  Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial.

Authors:  Daniel H Solomon; Rajesh Garg; Bing Lu; Derrick J Todd; Emileigh Mercer; Tabatha Norton; Elena Massarotti
Journal:  Arthritis Care Res (Hoboken)       Date:  2014-08       Impact factor: 4.794

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.